An update on the long-acting insulin analogue glargine

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 1, 2006, Pages 1-11

  Thisted, Henriette ^a,b   Johnsen, Søren Paaske ^b   Rungby, Jørgen ^a,b  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT;

CLINICAL TRIAL; CONTINUOUS SUBCUTANEOUS INSULIN INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SHORT SURVEY; SYSTEMATIC REVIEW;

BLOOD GLUCOSE; CHILD; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33745834801     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_352.x     Document Type: Short Survey

References (50)

1. Albright, E. S., R. Desmond & D. S. Bell: Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004, 27, 632-633.
2. Alemzadeh, R., T. Berhe & D. T. Wyatt: Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics 2005, 115, 1320-1324.
3. Alemzadeh, R., J. N. Ellis, M. K. Holzum, E. A. Parton & D. T. Wyatt: Beneficial effects of continuous subcutaneous insulin infusion and flexible multiple daily insulin regimen using insulin glargine in type 1 diabetes. Pediatrics 2004, 114, e91-e95.
4. Chase, H. P., B. Dixon, J. Pearson, R. Fiallo-Scharer, P. Walravens, G. Klingensmith, M. Rewers & S. K. Garg: Reduced hypoglycemic episodes and unproved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J. Pediatr. 2003, 143, 737-740.
5. Colino, E., M. Lopez-Capape, L. Golmayo, M. A. Alvarez, M. Alonso & R. Barrio: Therapy with insulin glargine (Lantus(R)) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res. Clin. Prac. 2005, 70, 1-7.
6. Davies, M., F. Storms, S. Shutler, M. Bianchi-Biscay & R. Gomis: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005, 28, 1282-1288.
7. Dixon, B., H. Peter Chase, J. Burdick, R. Fiallo-Scharer, P. Walravens, G. Klingensmith, M. Rewers & S. K. Garg: Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatric Diabetes 2005, 6, 150-154.
8. Doyle, E. A., S. A. Weinzimer, A. T. Steffen, J. A. Ahern, M. Vincent & W. V. Tamborlane: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004, 27, 1554-1558.
9. Fahlen, M., B. Eliasson & A. Oden: Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine. Diabet. Med 2005, 22, 382-386.
10. Fischer, J. S., T. McLaughlin, L. Loza, R. Beauchamp, S. Schwartz & M. Kipnes: The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr. Med. Res. Opin. 2004, 20, 1703-1710.
11. Fonseca, V., D. S. Bell, S. Berger, S. Thomson & T. E. Mecca: A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Amer. J. Med. Sci. 2004, 328, 274-280.
12. Fritsche, A., M. A. Schweitzer & H. U. Haring: Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann. Intern. Med. 2003, 138, 952-959.
13. Fulcher, G. R., R. E. Gilbert & D. K. Yue: Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Int. Med. J. 2005, 35, 536-542.
14. Gallen, I. W. & C. Carter: Prospective audit of the introduction of insulin glargine (lantus) into clinical practice in type 1 diabetic patients. Diabetes Care 2003, 26, 3352-3353.
15. Garg, S. K., P. A. Gottlieb, M. E. Hisatomi, A. D'Souza, A. J. Walker, K. E. Izuora & H. P. Chase: Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res. Clin. Pract. 2004a, 66, 49-56.
16. Garg, S. K., J. M. Paul, J. I. Karsten, L. Menditto & P. A. Gottlieb: Reduced severe hypoglycemia with insulin glargine in intensively treated adults with type 1 diabetes. Diabetes Technol. Therap. 2004b, 6, 589-595.
17. Garg, S. K., A. J. Walker, H. K. Hoff, A. O. D'Souza, P. A. Gottlieb & H. P. Chase: Glycemic parameters with multiple daily injections using insulin glargine versus insulin pump. Diabetes Technol. Therap. 2004c, 6, 9-15.
18. Hamann, A., S. Matthaei, C. Rosak & L. Silvestre: A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003, 26, 1738-1744.
19. Harmel, A. P. & R. Mathur: Similar A1C outcomes in type 1 diabetic patients undergoing intensive diabetes management with preprandial rapid-acting insulin and either CSII or glargine. Diabetes Care 2004, 27, 272-273.
20. Hathout, E. H., L. Fujishige, J. Geach, M. Ischandar, S. Maruo & J. W. Mace: Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol. Therap. 2003, 5, 801-806.
21. Herman, W. H., L. L. Ilag, S. L. Johnson, C. L. Martin, J. Sinding, H. A. Al, C. D. Plunkett, F. B. Laporte, R. Burke, M. B. Brown, J. B. Halter & P. Raskin: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care 2005, 28, 1568-1573.
22. Hershon, K. S., T. C. Blevins, T. C. Blevins & T. C. Blevins: Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr. Pract. 2004, 10, 10-17.
23. Hirsch, I. B., B. W. Bode, S. Garg, W. S. Lane, A. Sussman, P. Hu, O. M. Santiago & J. W. Kolaczynski: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005, 28, 533-538.
24. HOE 901/2004 Study Investigators Group: Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabet. Med. 2003, 20, 545-551.
25. Jackson, A., C. Ternand, C. Brunzell, T. Kleinschmidt, D. Dew, C. Milla & A. Moran: Insulin glargine improves hemoglobin A1c in children and adolescents with poorly controlled type 1 diabetes. Pediarr. Diabetes 2003, 4, 64-69.
26. Janka, H. U., G. Plewe, M. C. Riddle, C. Kliebe-Frisch, M. A. Schweitzer & H. Yki-Jarvinen: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005, 28, 254-259.
27. Kudva, Y. C., A. Basu, G. D. Jenkins, G. M. Pons, L. L. Quandt, J. A. Gebel, D. A. Vogelsang, S. A. Smith, R. A. Rizza & W. L. Isley: Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005, 28, 10-14.
28. Lepore, G., A. R. Dodesini, I. Nosari & R. Trevisan: Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study. Diabetes Nutr. Metab. 2004, 17, 84-89.
29. Lepore, G., A. R. Dodesini, I. Nosari & R. Trevisan: Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment. Diabetes Care 2003, 26, 1321-1322.
30. Malone, J. K., S. Bai, B. N. Campaigne, J. Reviriego & B. Ugendre-Ferrante: Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes. Diabet. Med 2005, 22, 374-381.
31. Malone, J. K., L. F. Kerr, B. N. Campaigne, R. A. Sachson & J. H. Holcombe: Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin. Therap. 2004, 26, 2034-2044.
32. Massi, B. M., E. Humburg, A. Dressler & M. Ziemen: A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm. Metab. Res. 2003, 35, 189-196.
33. Mohn, A., S. Strang, K. Wernicke-Panten, A. M. Lang, J. A. Edge & D. B. Dunger: Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen. Diabetes Care 2000, 23, 557-559.
34. Murphy, N. P., S. M. Keane, K. K. Ong, M. Ford-Adams, J. A. Edge, C. L. Acerini & D. B. Dunger: Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens. Diabetes Care 2003, 26, 799-804.
35. Pieber, T. R., I. Eugene-Jolchine & E. Derobert: Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000, 23, 157-162.
36. Porcellati, F., P. Rossetti, S. Pampanelli, C. G. Fanelli, E. Torlone, L. Scionti, G. Perriello & G. B. Bolli: Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet. Med. 2004, 21, 1213-1220.
37. Raskin, P., E. Allen, P. Hollander, A. Lewin, R. A. Gabbay, P. Hu, B. Bode & A. Garber: Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005, 28, 260-265.
38. Raskin, P., L. Klaff, R. Bergenstal, J. P. Halle, D. Donley & T. Mecca: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000, 23, 1666-1671.
39. Ratner, R. E., I. B. Hirsch, J. L. Neifing, S. K. Garg, T. E. Mecca & C. A. Wilson: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000, 23, 639-643.
40. Riddle, M. C., J. Rosenstock & J. Gerich: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003, 26, 3080-3086.
41. Rosenstock, J., G. Dailey, M. Massi-Benedetti, A. Fritsche, Z. Lin & A. Salzman: Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005, 28, 950-955.
42. Rosenstock, J., G. Park & J. Zimmerman: Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000, 23, 1137-1142.
43. Rosenstock, J., S. L. Schwartz, C. M. Clark, Jr., G. D. Park, D. W. Donley & M. B. Edwards: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001, 24, 631-636.
44. Rossetti, P., S. Pampanelli, C. Fanelli, F. Porcellati, E. Costa, E. Torlone, L. Scionti & G. B. Bolli: Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003, 26, 1490-1496.
45. Schiaffini, R., P. Ciampalini, S. Spera, M. Cappa & A. Crino: An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes. Diabetes Metab. Res. Rev. 2005, 21, 347-352.
46. Schober, E., E. Schoenle, J. Van Dyk & K. Wernicke-Panten: Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J. Pediatr. Endocrinol. Metab. 2002, 15, 369-376.
47. Scholtz, H. E., S. G. Pretorius, D. H. Wessels & R. H. Becker: Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 2005, 48, 1988-1995.
48. Standl, E., S. Maxeiner, S. Raptis, Z. Karimi-Anderesi & M. A. Schweitzer: Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care 2005, 28, 419-420.
49. Witthaus, E., J. Stewart & C. Bradley: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet. Med 2001, 18, 619-625.
50. Yki-Järvinen, H., A. Dressler & M. Ziemen: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000, 23, 1130-1136.